---
title: "OKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293487942.md"
description: "OKYO Pharma's Chief Development Officer, Gary S. Jacob, increased his stake by purchasing 3,500 shares at $1.40 each on July 22, 2026, signaling insider confidence ahead of the planned Phase 3 trial for urcosimod in neuropathic corneal pain scheduled for late 2026. While analysts maintain a 'Buy' rating with a $5 target, TipRanks' AI model rates the stock as Neutral due to weak financials and bearish technical indicators."
datetime: "2026-07-22T14:27:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293487942.md)
  - [en](https://longbridge.com/en/news/293487942.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293487942.md)
generator: "portal-rs"
---

# OKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial

An update from OKYO Pharma Limited Sponsored ADR ( (OKYO) ) is now available.

OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on innovative treatments for neuropathic corneal pain and anterior segment eye diseases, with its ordinary shares traded on the Nasdaq Capital Market. The company intends to start a global Phase 3 pivotal trial in the second half of 2026, enrolling around 111 patients to evaluate a single-dose regimen of urcosimod for NCP.

On July 22, 2026, OKYO Pharma disclosed that Chief Development Officer and Director Gary S. Jacob increased his personal stake in the company by purchasing 3,500 ordinary shares on Nasdaq at $1.40 per share. This transaction, which lifted his total holding to 112,420 shares, signals insider confidence in OKYO’s strategy and upcoming clinical milestones, and may be viewed positively by investors monitoring leadership alignment with shareholder interests. 

The most recent analyst rating on (OKYO) stock is a Buy  
 with a $5.00 price target.  
 To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock,  
 see the OKYO Stock Forecast page. 

**Spark’s Take on OKYO Stock**

According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and negative free cash flow implying continued funding needs). Technical indicators also lean bearish with price below key moving averages and a negative MACD, despite oversold conditions. Valuation support is limited because the company is loss-making (negative P/E) and no dividend yield is provided.

To see Spark’s full report on OKYO stock,  
 click here. 

**More about OKYO Pharma Limited Sponsored ADR**

OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and anterior segment eye diseases. The company’s ordinary shares are listed on the Nasdaq Capital Market, and it plans to launch a global Phase 3 pivotal trial in the second half of 2026 to test a single-dose regimen of urcosimod in approximately 111 NCP patients.

By advancing urcosimod into late-stage development, OKYO Pharma is seeking to strengthen its position in the niche ophthalmic pain market, where treatment options remain limited. The planned Phase 3 trial underscores its strategy to build clinical evidence around NCP and potentially support future regulatory submissions if the study proves successful. 

**Average Trading Volume:** 90,268

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $70.38M

### Related Stocks

- [OKYO.US](https://longbridge.com/en/quote/OKYO.US.md)

## Related News & Research

- [OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial](https://longbridge.com/en/news/293646761.md)
- [OKYO Pharma to Present Ophthalmology Pipeline Ahead of Phase 3 Urcosimod Trial](https://longbridge.com/en/news/293350393.md)
- [Dogwood Therapeutics to host virtual KOL event on Halneuron for chemotherapy-induced neuropathic pain](https://longbridge.com/en/news/296106790.md)
- [The Bull Case For Vertex (VRTX) Could Change Following Upgraded 2026 Guidance And Pipeline Momentum - Learn Why](https://longbridge.com/en/news/296583461.md)
- [Gaush Neotech signs five-year exclusive global distribution deal with Heidelberg for T3 corneal confocal microscopy outside China](https://longbridge.com/en/news/296103795.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**